PT2707391T - Anticorpos contra her3 - Google Patents
Anticorpos contra her3Info
- Publication number
- PT2707391T PT2707391T PT127197630T PT12719763T PT2707391T PT 2707391 T PT2707391 T PT 2707391T PT 127197630 T PT127197630 T PT 127197630T PT 12719763 T PT12719763 T PT 12719763T PT 2707391 T PT2707391 T PT 2707391T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies against
- against her3
- her3
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305583 | 2011-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2707391T true PT2707391T (pt) | 2018-02-06 |
Family
ID=46046250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT127197630T PT2707391T (pt) | 2011-05-13 | 2012-05-11 | Anticorpos contra her3 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9346883B2 (pt) |
EP (1) | EP2707391B1 (pt) |
DK (1) | DK2707391T3 (pt) |
ES (1) | ES2657862T3 (pt) |
NO (1) | NO2707391T3 (pt) |
PL (1) | PL2707391T3 (pt) |
PT (1) | PT2707391T (pt) |
WO (1) | WO2012156309A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013002046A (es) | 2010-08-20 | 2013-04-03 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3). |
KR20140099315A (ko) * | 2011-12-05 | 2014-08-11 | 노파르티스 아게 | Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
SI3110849T1 (sl) * | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
PL3365373T3 (pl) | 2015-10-23 | 2021-08-23 | Merus N.V. | Molekuły wiążące, które hamują wzrost nowotworu |
CN110650752A (zh) | 2017-03-31 | 2020-01-03 | 美勒斯公司 | 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体 |
CA3064333A1 (en) * | 2017-05-29 | 2018-12-06 | Gamamabs Pharma | Cancer-associated immunosuppression inhibitor |
BR112020002695A2 (pt) | 2017-08-09 | 2020-08-25 | Merus N.V. | anticorpos que se ligam à egfr e cmet |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
CA2156725A1 (en) | 1993-02-22 | 1994-09-01 | Warren S. Pear | Production of high titer helper-free retroviruses by transient transfection |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
DK1522590T3 (da) | 2000-06-28 | 2009-12-21 | Glycofi Inc | Fremgangsmåde til fremstilling af modificerede glykoproteiner |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
DK2129396T3 (da) | 2007-02-16 | 2013-11-25 | Merrimack Pharmaceuticals Inc | Antistoffer mod ErbB3 og anvendelser deraf |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
-
2012
- 2012-05-11 NO NO12719763A patent/NO2707391T3/no unknown
- 2012-05-11 ES ES12719763.0T patent/ES2657862T3/es active Active
- 2012-05-11 PT PT127197630T patent/PT2707391T/pt unknown
- 2012-05-11 WO PCT/EP2012/058769 patent/WO2012156309A1/en active Application Filing
- 2012-05-11 DK DK12719763.0T patent/DK2707391T3/en active
- 2012-05-11 PL PL12719763T patent/PL2707391T3/pl unknown
- 2012-05-11 US US14/116,562 patent/US9346883B2/en active Active
- 2012-05-11 EP EP12719763.0A patent/EP2707391B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9346883B2 (en) | 2016-05-24 |
ES2657862T3 (es) | 2018-03-07 |
NO2707391T3 (pt) | 2018-04-07 |
WO2012156309A1 (en) | 2012-11-22 |
PL2707391T3 (pl) | 2018-04-30 |
EP2707391B1 (en) | 2017-11-08 |
US20140141019A1 (en) | 2014-05-22 |
EP2707391A1 (en) | 2014-03-19 |
DK2707391T3 (en) | 2018-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2400016I1 (hu) | FCRN elleni antitestek | |
HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
IL259826A (en) | Anti-alphabetatisiar antibody | |
IL264558A (en) | Anti–il–23p19 antibodies | |
GB201103955D0 (en) | Antibodies | |
GB201112056D0 (en) | Antibodies | |
HK1204571A1 (en) | Protease-regulated antibodies | |
HK1210192A1 (en) | Anti-siglec-15 antibodies siglec-15 | |
EP2788377A4 (en) | HER3 ANTIBODIES AND USES THEREOF | |
EP2722343A4 (en) | ANTI-ERBB3 ANTIBODIES | |
PT2707391T (pt) | Anticorpos contra her3 | |
TWI563004B (en) | Anti-hxcr1 antibody | |
HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
HK1200852A1 (en) | New antibodies against phosphorylcholine | |
EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
GB201116342D0 (en) | Antigen combinations |